

MR

10. (Amended) The use as claimed in claim 8 [or claim 9], characterized in that said pharmaceutical composition is present in the form of a gel, an ointment or an isotonic solution.

AB

11. (Amended) The use as claimed in claim 8 [any one of claims 8 to 10], characterized in that said pharmaceutical composition is adapted to administration by local external application or by the parenteral route.

AB

14. (Amended) The use as claimed in claim 12 [or claim 13], characterized in that said pharmaceutical composition is present in the form of eye drops or an ophthalmic ointment.--

Correspondence Address

All future correspondence concerning the above-identified U.S. patent application should be addressed to the undersigned attorney at the following address:

Thomas W. Tolpin
Welsh & Katz, Ltd.
22nd Floor
120 South Riverside Plaza
Chicago, IL 60606
Phone: (312) 655-1500
Fax: (312) 655-1501

Remarks

Reconsideration of the subject U.S. patent application in light of the present Amendment and Remarks is respectfully requested.

Authorization is hereby given to charge any deficiency in fees or any other fees in connection with the subject patent application to our Deposit Account No. 23-0920.

Claims 5-7, 10, 11, and 14 have been amended to avoid multiple dependency and better conform to U.S. practice.

A clean version of the entire set of pending claims is enclosed in accordance with 37 CFR 1.121 (c) (3).